Amneal Pharmaceuticals Inc. Insider Trading

AMRX

Last 12 months

Insiders sold $9.82M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. EVP, Chief Legal Officer Jason B. Daly sold $3.77M on Aug 12, 86% of their stake, outside a plan. The last open-market buy by an executive or director was in Dec 2021.

Net open-market

−$9.82M

0 buys · 6 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Dec 2021

Dec 17, 2021

Get an email when AMRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 13	John Kiely Director	SoldNo plan	50,000	$17.64	882K	20%	Form 4
Aug 12	Nikita Shah Executive Vice President	SoldNo plan	146,403	$17.51	$2.56M	37%	Form 4
Aug 11 – 12	Jason B. Daly EVP, Chief Legal Officer	SoldNo plan 2 parts	216,613	$17.41 average	$3.77M	86%	Form 4
May 11	Deborah M. Autor Director	SoldNo plan	34,819	$12.94	451K	27%	Form 4
Nov 17, 2025	Ted C Nark Director	SoldNo plan	50,000	$11.72	586K	15%	Form 4
Nov 12, 2025	Nikita Shah Executive Vice President	SoldNo plan	131,856	$11.92	$1.57M	47%	Form 4
Aug 27, 2025	John Kiely Director	SoldNo plan	32,000	$9.23	295K	12%	Form 4
Aug 22, 2025 – Aug 25, 2025	Nikita Shah Executive Vice President	SoldNo plan 2 parts	120,832	$9.65 average	$1.17M	45%	Form 4
Aug 20, 2025	Andrew S Boyer Executive Vice President	SoldNo plan	279,244	$9.38	$2.62M	65%	Form 4
Aug 13, 2025 – Aug 15, 2025	Tasos Konidaris Executive Vice President & CFO	SoldNo plan 3 parts	499,730	$9.33 average	$4.66M	80%	Form 4
Aug 14, 2025	Nikita Shah Executive Vice President	SoldNo plan	71,694	$9.29	666K	21%	Form 4
Aug 12, 2025	Nikita Shah Executive Vice President	SoldNo plan	50,000	$9.04	452K	13%	Form 4
Aug 12, 2025	Jason B. Daly EVP, Chief Legal Officer	SoldNo plan	22,000	$9.05	199K	67%	Form 4
Aug 12, 2025	Andrew S Boyer Executive Vice President	SoldNo plan	33,436	$9.05	303K	12%	Form 4
Jun 16, 2025	Gautam Patel Director	Sold10b5-1 plan	94,906	$8.02	761K	5.6%	Form 4
Jun 10, 2025	Gautam Patel Director	SoldNo plan	56,426	$8.02	453K	3.2%	Form 4
May 16, 2025	Nikita Shah Executive Vice President	SoldNo plan	49,140	$7.58	372K	11%	Form 4
May 12, 2025	John Kiely Director	SoldNo plan	50,000	$7.59	380K	16%	Form 4
May 2, 2025 – May 5, 2025	Gautam Patel Director	Sold10b5-1 plan 2 parts	8,668	$8.00 average	69K	0.5%	Form 4
Apr 1, 2025	Gautam Patel Director	Sold10b5-1 plan	80,000	$8.30	664K	4.4%	Form 4
Mar 14, 2025	Tushar Bhikhubhai Patel Large holder	SoldNo plan	5,000,000	$8.35	$41.8M	9.3%	Form 4
Mar 5, 2025 – Mar 6, 2025	Jason B. Daly EVP, Chief Legal Officer	SoldNo plan 2 parts	90,000	$8.80 average	792K	73%	Form 4
Mar 5, 2025	Andrew S Boyer Executive Vice President	SoldNo plan	125,000	$8.89	$1.11M	30%	Form 4
Mar 5, 2025	Tasos Konidaris Executive Vice President & CFO	SoldNo plan	100,000	$8.91	891K	14%	Form 4
Mar 5, 2025	Emily Peterson Alva Director	SoldNo plan	80,000	$8.90	712K	32%	Form 4
Mar 3, 2025	Gautam Patel Director	Sold10b5-1 plan	80,000	$8.90	712K	4.2%	Form 4
Feb 3, 2025	Gautam Patel Director	Sold10b5-1 plan	80,000	$8.14	651K	4.1%	Form 4
Jan 8, 2025	Gautam Patel Director	Sold10b5-1 plan	62,590	$8.01	501K	3.1%	Form 4
Jan 2, 2025	Gautam Patel Director	Sold10b5-1 plan	17,410	$8.01	139K	0.8%	Form 4
Nov 22, 2024	John Kiely Director	SoldNo plan	17,058	$8.38	143K	6.0%	Form 4
Nov 21, 2024 – Nov 22, 2024	Deborah M. Autor Director	SoldNo plan 2 parts	40,000	$8.35 average	334K	43%	Form 4
Nov 21, 2024	Jason B. Daly SVP, Chief Legal Officer	SoldNo plan	13,665	$8.40	115K	100%	Form 4
Nov 15, 2024	Jason B. Daly SVP, Chief Legal Officer	SoldNo plan	43,657	$8.61	376K	76%	Form 4

Aug 13No plan
John Kiely
Director · sold 50,000 at $17.64
882K
20% of stake
Aug 12No plan
Nikita Shah
Executive Vice President · sold 146,403 at $17.51
$2.56M
37% of stake
Aug 11 – 12No plan
Jason B. Daly
EVP, Chief Legal Officer · sold 216,613 at avg $17.41
$3.77M
86% of stake
May 11No plan
Deborah M. Autor
Director · sold 34,819 at $12.94
451K
27% of stake
Nov 17, 2025No plan
Ted C Nark
Director · sold 50,000 at $11.72
586K
15% of stake
Nov 12, 2025No plan
Nikita Shah
Executive Vice President · sold 131,856 at $11.92
$1.57M
47% of stake
Aug 27, 2025No plan
John Kiely
Director · sold 32,000 at $9.23
295K
12% of stake
Aug 22, 2025 – Aug 25, 2025No plan
Nikita Shah
Executive Vice President · sold 120,832 at avg $9.65
$1.17M
45% of stake
Aug 20, 2025No plan
Andrew S Boyer
Executive Vice President · sold 279,244 at $9.38
$2.62M
65% of stake
Aug 13, 2025 – Aug 15, 2025No plan
Tasos Konidaris
Executive Vice President & CFO · sold 499,730 at avg $9.33
$4.66M
80% of stake
Aug 14, 2025No plan
Nikita Shah
Executive Vice President · sold 71,694 at $9.29
666K
21% of stake
Aug 12, 2025No plan
Nikita Shah
Executive Vice President · sold 50,000 at $9.04
452K
13% of stake
Aug 12, 2025No plan
Jason B. Daly
EVP, Chief Legal Officer · sold 22,000 at $9.05
199K
67% of stake
Aug 12, 2025No plan
Andrew S Boyer
Executive Vice President · sold 33,436 at $9.05
303K
12% of stake
Jun 16, 202510b5-1 plan
Gautam Patel
Director · sold 94,906 at $8.02
761K
5.6% of stake
Jun 10, 2025No plan
Gautam Patel
Director · sold 56,426 at $8.02
453K
3.2% of stake
May 16, 2025No plan
Nikita Shah
Executive Vice President · sold 49,140 at $7.58
372K
11% of stake
May 12, 2025No plan
John Kiely
Director · sold 50,000 at $7.59
380K
16% of stake
May 2, 2025 – May 5, 202510b5-1 plan
Gautam Patel
Director · sold 8,668 at avg $8.00
69K
0.5% of stake
Apr 1, 202510b5-1 plan
Gautam Patel
Director · sold 80,000 at $8.30
664K
4.4% of stake
Mar 14, 2025No plan
Tushar Bhikhubhai Patel
Large holder · sold 5,000,000 at $8.35
$41.8M
9.3% of stake
Mar 5, 2025 – Mar 6, 2025No plan
Jason B. Daly
EVP, Chief Legal Officer · sold 90,000 at avg $8.80
792K
73% of stake
Mar 5, 2025No plan
Andrew S Boyer
Executive Vice President · sold 125,000 at $8.89
$1.11M
30% of stake
Mar 5, 2025No plan
Tasos Konidaris
Executive Vice President & CFO · sold 100,000 at $8.91
891K
14% of stake
Mar 5, 2025No plan
Emily Peterson Alva
Director · sold 80,000 at $8.90
712K
32% of stake
Mar 3, 202510b5-1 plan
Gautam Patel
Director · sold 80,000 at $8.90
712K
4.2% of stake
Feb 3, 202510b5-1 plan
Gautam Patel
Director · sold 80,000 at $8.14
651K
4.1% of stake
Jan 8, 202510b5-1 plan
Gautam Patel
Director · sold 62,590 at $8.01
501K
3.1% of stake
Jan 2, 202510b5-1 plan
Gautam Patel
Director · sold 17,410 at $8.01
139K
0.8% of stake
Nov 22, 2024No plan
John Kiely
Director · sold 17,058 at $8.38
143K
6.0% of stake
Nov 21, 2024 – Nov 22, 2024No plan
Deborah M. Autor
Director · sold 40,000 at avg $8.35
334K
43% of stake
Nov 21, 2024No plan
Jason B. Daly
SVP, Chief Legal Officer · sold 13,665 at $8.40
115K
100% of stake
Nov 15, 2024No plan
Jason B. Daly
SVP, Chief Legal Officer · sold 43,657 at $8.61
376K
76% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AMRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AMRX

CompareIntrinsic value

UTHRUnited Therapeutics Corporation

$608.49+1.19%78

BMRNBiomarin Pharmaceutical Inc.

$57.13+2.64%47

RPRXRoyalty Pharma plc

$67.56+1.75%19

ALNYAlnylam Pharmaceuticals Inc

$161.08+0.74%81

PRGOPerrigo Company plc

$15.83+0.83%17

SRPTSarepta Therapeutics Inc.

$18.99+2.43%51

ALKSAlkermes plc

$45.90+0.46%36

JAZZJazz Pharmaceuticals plc

$234.66+2.14%58

Held by ETFs

AMRX is in 91 US ETFs. The largest of them, with AMRX's weight in each:

Spot a number that looks wrong? Check it in AMRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AMRX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.